Systemic metabolomic changes in blood samples of lung cancer patients identified by gas chromatography Time-Of-Flight mass spectrometry

Suzanne Miyamoto, Sandra L. Taylor, Dinesh K. Barupal, Ayumu Taguchi, Gert Wohlgemuth, William R. Wikoff, Ken Y Yoneda, David R Gandara, Samir M. Hanash, Kyoungmi Kim, Oliver Fiehn

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Lung cancer is a leading cause of cancer deaths worldwide. Metabolic alterations in tumor cells coupled with systemic indicators of the host response to tumor development have the potential to yield blood profiles with clinical utility for diagnosis and monitoring of treatment. We report results from two separate studies using gas chromatography time-of-flight mass spectrometry (GC-TOF MS) to profile metabolites in human blood samples that significantly differ from non-small cell lung cancer (NSCLC) adenocarcinoma and other lung cancer cases. Metabolomic analysis of blood samples from the two studies yielded a total of 437 metabolites, of which 148 were identified as known compounds and 289 identified as unknown compounds. Differential analysis identified 15 known metabolites in one study and 18 in a second study that were statistically different (p-values <0.05). Levels of maltose, palmitic acid, glycerol, ethanolamine, glutamic acid, and lactic acid were increased in cancer samples while amino acids tryptophan, lysine and histidine decreased. Many of the metabolites were found to be significantly different in both studies, suggesting that metabolomics appears to be robust enough to find systemic changes from lung cancer, thus showing the potential of this type of analysis for lung cancer detection.

Original languageEnglish (US)
Pages (from-to)192-210
Number of pages19
JournalMetabolites
Volume5
Issue number2
DOIs
StatePublished - Apr 9 2015

Fingerprint

Metabolomics
Metabolites
Gas chromatography
Gas Chromatography
Mass spectrometry
Lung Neoplasms
Mass Spectrometry
Blood
Tumors
Neoplasms
Cells
Ethanolamine
Maltose
Palmitic Acid
Histidine
Non-Small Cell Lung Carcinoma
Tryptophan
Glycerol
Lysine
Glutamic Acid

Keywords

  • Blood
  • Lung cancer
  • Mass spectrometry
  • Metabolomics

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Biology

Cite this

Miyamoto, S., Taylor, S. L., Barupal, D. K., Taguchi, A., Wohlgemuth, G., Wikoff, W. R., ... Fiehn, O. (2015). Systemic metabolomic changes in blood samples of lung cancer patients identified by gas chromatography Time-Of-Flight mass spectrometry. Metabolites, 5(2), 192-210. https://doi.org/10.3390/metabo5020192

Systemic metabolomic changes in blood samples of lung cancer patients identified by gas chromatography Time-Of-Flight mass spectrometry. / Miyamoto, Suzanne; Taylor, Sandra L.; Barupal, Dinesh K.; Taguchi, Ayumu; Wohlgemuth, Gert; Wikoff, William R.; Yoneda, Ken Y; Gandara, David R; Hanash, Samir M.; Kim, Kyoungmi; Fiehn, Oliver.

In: Metabolites, Vol. 5, No. 2, 09.04.2015, p. 192-210.

Research output: Contribution to journalArticle

Miyamoto, Suzanne ; Taylor, Sandra L. ; Barupal, Dinesh K. ; Taguchi, Ayumu ; Wohlgemuth, Gert ; Wikoff, William R. ; Yoneda, Ken Y ; Gandara, David R ; Hanash, Samir M. ; Kim, Kyoungmi ; Fiehn, Oliver. / Systemic metabolomic changes in blood samples of lung cancer patients identified by gas chromatography Time-Of-Flight mass spectrometry. In: Metabolites. 2015 ; Vol. 5, No. 2. pp. 192-210.
@article{f8bcb9a039954889bc183dade79bfb0c,
title = "Systemic metabolomic changes in blood samples of lung cancer patients identified by gas chromatography Time-Of-Flight mass spectrometry",
abstract = "Lung cancer is a leading cause of cancer deaths worldwide. Metabolic alterations in tumor cells coupled with systemic indicators of the host response to tumor development have the potential to yield blood profiles with clinical utility for diagnosis and monitoring of treatment. We report results from two separate studies using gas chromatography time-of-flight mass spectrometry (GC-TOF MS) to profile metabolites in human blood samples that significantly differ from non-small cell lung cancer (NSCLC) adenocarcinoma and other lung cancer cases. Metabolomic analysis of blood samples from the two studies yielded a total of 437 metabolites, of which 148 were identified as known compounds and 289 identified as unknown compounds. Differential analysis identified 15 known metabolites in one study and 18 in a second study that were statistically different (p-values <0.05). Levels of maltose, palmitic acid, glycerol, ethanolamine, glutamic acid, and lactic acid were increased in cancer samples while amino acids tryptophan, lysine and histidine decreased. Many of the metabolites were found to be significantly different in both studies, suggesting that metabolomics appears to be robust enough to find systemic changes from lung cancer, thus showing the potential of this type of analysis for lung cancer detection.",
keywords = "Blood, Lung cancer, Mass spectrometry, Metabolomics",
author = "Suzanne Miyamoto and Taylor, {Sandra L.} and Barupal, {Dinesh K.} and Ayumu Taguchi and Gert Wohlgemuth and Wikoff, {William R.} and Yoneda, {Ken Y} and Gandara, {David R} and Hanash, {Samir M.} and Kyoungmi Kim and Oliver Fiehn",
year = "2015",
month = "4",
day = "9",
doi = "10.3390/metabo5020192",
language = "English (US)",
volume = "5",
pages = "192--210",
journal = "Metabolites",
issn = "2218-1989",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

TY - JOUR

T1 - Systemic metabolomic changes in blood samples of lung cancer patients identified by gas chromatography Time-Of-Flight mass spectrometry

AU - Miyamoto, Suzanne

AU - Taylor, Sandra L.

AU - Barupal, Dinesh K.

AU - Taguchi, Ayumu

AU - Wohlgemuth, Gert

AU - Wikoff, William R.

AU - Yoneda, Ken Y

AU - Gandara, David R

AU - Hanash, Samir M.

AU - Kim, Kyoungmi

AU - Fiehn, Oliver

PY - 2015/4/9

Y1 - 2015/4/9

N2 - Lung cancer is a leading cause of cancer deaths worldwide. Metabolic alterations in tumor cells coupled with systemic indicators of the host response to tumor development have the potential to yield blood profiles with clinical utility for diagnosis and monitoring of treatment. We report results from two separate studies using gas chromatography time-of-flight mass spectrometry (GC-TOF MS) to profile metabolites in human blood samples that significantly differ from non-small cell lung cancer (NSCLC) adenocarcinoma and other lung cancer cases. Metabolomic analysis of blood samples from the two studies yielded a total of 437 metabolites, of which 148 were identified as known compounds and 289 identified as unknown compounds. Differential analysis identified 15 known metabolites in one study and 18 in a second study that were statistically different (p-values <0.05). Levels of maltose, palmitic acid, glycerol, ethanolamine, glutamic acid, and lactic acid were increased in cancer samples while amino acids tryptophan, lysine and histidine decreased. Many of the metabolites were found to be significantly different in both studies, suggesting that metabolomics appears to be robust enough to find systemic changes from lung cancer, thus showing the potential of this type of analysis for lung cancer detection.

AB - Lung cancer is a leading cause of cancer deaths worldwide. Metabolic alterations in tumor cells coupled with systemic indicators of the host response to tumor development have the potential to yield blood profiles with clinical utility for diagnosis and monitoring of treatment. We report results from two separate studies using gas chromatography time-of-flight mass spectrometry (GC-TOF MS) to profile metabolites in human blood samples that significantly differ from non-small cell lung cancer (NSCLC) adenocarcinoma and other lung cancer cases. Metabolomic analysis of blood samples from the two studies yielded a total of 437 metabolites, of which 148 were identified as known compounds and 289 identified as unknown compounds. Differential analysis identified 15 known metabolites in one study and 18 in a second study that were statistically different (p-values <0.05). Levels of maltose, palmitic acid, glycerol, ethanolamine, glutamic acid, and lactic acid were increased in cancer samples while amino acids tryptophan, lysine and histidine decreased. Many of the metabolites were found to be significantly different in both studies, suggesting that metabolomics appears to be robust enough to find systemic changes from lung cancer, thus showing the potential of this type of analysis for lung cancer detection.

KW - Blood

KW - Lung cancer

KW - Mass spectrometry

KW - Metabolomics

UR - http://www.scopus.com/inward/record.url?scp=85016919890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016919890&partnerID=8YFLogxK

U2 - 10.3390/metabo5020192

DO - 10.3390/metabo5020192

M3 - Article

AN - SCOPUS:85016919890

VL - 5

SP - 192

EP - 210

JO - Metabolites

JF - Metabolites

SN - 2218-1989

IS - 2

ER -